Kartrider: Drift’s Preseason Brings Arcade Thrills to Kart Racing Fans on PC and Mobile Platforms
12.1.2023 07:16:00 EET | Business Wire | Press release
Starting today, KartRider: Drift , Nexon’s highly anticipated free-to-play kart racing party game, is available to download and play on PC and mobile platforms via Steam, Nexon Launcher, iOS App Store, and Google Play.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230111006031/en/
KartRider: Drift from Nexon America now available on Steam, iOS, and Android (Graphic: Business Wire)
During Preseason, racers can test their mettle on bright, colorful tracks against PC and mobile racers from around the globe, rendered in stunning Unreal® Engine 4 graphics.
With unique characters and karts, racers have complete control over customization options to express themselves fully and cross the finish line in style! More characters, karts, accessories, and emotes can be unlocked via the Racing Pass, where racers can complete different daily challenges and event challenges. Premium challenges are also available with the purchase of a Premium Racing Pass.
Racers are trained and challenged through a unique License System in a series of meticulously designed courses. In Time Attack Mode, racers can then test their skills to top the leaderboards.
KartRider: Drift brings the deep kart customization that PC and mobile players expect, while delivering arcade-quality racing thrills to casual and seasoned players alike. Now’s the time for players to put the pedal to the metal – download KartRider: Drift and burn rubber!
NOTE FOR EDITORS:
KartRider: Drift’s Preseason launch on January 11 is only for PC (Steam, Nexon Launcher) and mobile (iOS, Android) players.
Playstation and Xbox console players will be able to join PC and mobile racers beginning with Season 1 (S1 launch to be announced at a later date).
Nexon’s KartRider Rush+ mobile racing game, launched in 2020, will continue to operate as a standalone title and does not share cross-play with KartRider: Drift.
Social Media: Twitch / Twitter / Instagram / Discord / Facebook / YouTube
About
Kartrider: Drift
KartRider: Drift is Nexon’s new multiplayer kart racing party game, taking inspiration from earlier titles in the KartRider franchise, delivering drift-fueled racing action and featuring multiple game modes and deep kart and character customization in stunning Unreal® Engine 4 graphics. Available on Steam, the Nexon Launcher, mobile (iOS and Android) during Preseason, and with Xbox and PlayStation consoles joining at the launch of Season 1, KartRider: Drift
offers free-to-play, online cross-platform play and progression to challenge friends regardless of the platform they choose.
Launched in 2004, the original KartRider was the first title in Nexon’s legendary kart racing series, and subsequently gained huge popularity in Asia and beyond, amassing more than 380 million players during the nineteen years since release. As a franchise, KartRider has established a strong brand across Asian markets and a huge eSports presence in Asia, with an official league starting in 2005. It continues to be the longest-running eSports league to date.
About
Nexon America Inc.
Founded in 2006, Nexon America Inc. delivers outstanding free-to-play online game expertise and live game support, taking the strengths of NEXON Co., Ltd. (“Nexon”) and applying them for uniquely western audiences. Nexon America has consistently sustained iconic franchises such as MapleStory and Mabinogi for more than a decade, which have gone on to break records and captivate players. With new projects on the horizon, Nexon America maintains the pioneering and innovative spirit of its parent company, employing its player-first approach, while designing the best possible gameplay experiences for the western market.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230111006031/en/
Contact information
North America
and LATAM
Brian Klotz, Nexon America
NA_pr@nexon.com
Europe and UK
Heaven Media
nexon@heavenmedia.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom